Trials / Completed
CompletedNCT02100514
Randomized Clinical Trial of Bococizumab (PF-04950615; RN316) in Subjects With Primary Hyperlipidemia or Mixed Dyslipidemia At Risk Of Cardiovascular Events
A 52 Week Phase 3 Double-blind, Randomized, Placebo-controlled, Parallel-group Study To Assess The Efficacy, Safety And Tolerability Of Pf-04950615 In Subjects With Primary Hyperlipidemia Or Mixed Dyslipidemia At Risk Of Cardiovascular Events
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 746 (actual)
- Sponsor
- Pfizer · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study is a multicenter, double-blind, randomized study to access the efficacy, safety and tolerability of Bococizumab (PF-04950615; RN316) in subjects with hyperlipidemia receiving background statin therapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Bococizumab (PF-04950615; RN316) | 150 mg every 2 weeks, subcutaneous injection for 52 weeks. |
| OTHER | Placebo | Subcutaneous injection every 2 weeks for 52 weeks. |
Timeline
- Start date
- 2014-10-28
- Primary completion
- 2016-07-15
- Completion
- 2017-07-10
- First posted
- 2014-04-01
- Last updated
- 2018-07-31
- Results posted
- 2017-07-21
Locations
223 sites across 12 countries: United States, Canada, Czechia, Finland, Netherlands, Norway, Poland, Puerto Rico, Singapore, South Korea, Sweden, United Kingdom
Source: ClinicalTrials.gov record NCT02100514. Inclusion in this directory is not an endorsement.